Polaryx Therapeutics, Inc. PLYX
—
2.09
(0.05)
(2.34%)
as of 25 Sep
- Market cap
- $106.7M
- P/E
- 0.0×
Follow PLYX
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Jun '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+2 more quarters Free account |
— | 8.55 | 3.45 | 13.53 |
Net Debt/EBITDA |
0.00 | 0.00 | 1.57 | 8.36 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
— | — | 0.00 | 0.00 | |
Operating CF/Net income |
0.85 | 0.00 | 0.81 | 0.99 | |
Capex/Depreciation |
— | 0.00 | — | — | |
Interest Coverage |
0.00 | — | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | — | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | — | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | — | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.02) | 0.00 | (0.04) | (0.03) | |
Cash per Share |
0.00 | 0.00 | 0.07 | 0.24 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.05 | 0.23 | |
Interest Debt per Share |
0.00 | — | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | 0.05 | 0.23 | |
Free Cash Flow |
(0.86) | (3.94) | (2.06) | (1.37) | |
Working Capital |
— | 4.57 | 2.49 | 10.94 | |
Capital Expenditures |
— | 0.00 | — | — | |
Net Current Asset Value |
0.00 | 4.57 | 2.49 | 10.94 | |
| Other line items | |||||
Quick Ratio |
— | 8.50 | 3.04 | 13.22 | |
Revenue per Share |
0.00 | — | 0.00 | 0.00 | |
Operating CF per Share |
(0.02) | 0.00 | (0.04) | (0.03) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Assets |
— | — | 4.25 | 5.91 | |
Capex to Sales |
— | 0.00 | — | — | |
Net Profit Margin |
0.00% | — | 0.00% | 0.00% |
Columns are period end dates